DrugPatentWatch Database Preview
AEMCOLO Drug Profile
Which patents cover Aemcolo, and what generic alternatives are available?
Aemcolo is a drug marketed by Cosmo Technologies and is included in one NDA. There are four patents protecting this drug.
This drug has twenty-six patent family members in nineteen countries.
The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin profile page.
Summary for AEMCOLO
| International Patents: | 26 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 13 |
| Clinical Trials: | 1 |
| Patent Applications: | 356 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | AEMCOLO at DailyMed |
Generic Entry Opportunity Date for AEMCOLO
Generic Entry Date for AEMCOLO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, DELAYED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for AEMCOLO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hunter Holmes Mcguire Veteran Affairs Medical Center | Phase 2 |
US Patents and Regulatory Information for AEMCOLO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cosmo Technologies | AEMCOLO | rifamycin | TABLET, DELAYED RELEASE;ORAL | 210910-001 | Nov 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Cosmo Technologies | AEMCOLO | rifamycin | TABLET, DELAYED RELEASE;ORAL | 210910-001 | Nov 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Cosmo Technologies | AEMCOLO | rifamycin | TABLET, DELAYED RELEASE;ORAL | 210910-001 | Nov 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Cosmo Technologies | AEMCOLO | rifamycin | TABLET, DELAYED RELEASE;ORAL | 210910-001 | Nov 16, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for AEMCOLO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20070028441 | Start Trial |
| Mexico | PA06014698 | Start Trial |
| China | 101317826 | Start Trial |
| South Korea | 101157486 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AEMCOLO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1763339 | 122019000048 | Germany | Start Trial | PRODUCT NAME: RIFAMYCIN SV; REGISTRATION NO/DATE: DE/H/5379/001/DC 20190509 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
